... Marrie said researchers will need to further investigate these areas to find out more information about what could be driving the higher death rates among those with MS and colorectal cancer. ...
Posted 10/20/2021
New evidence shows that stem cell transplantation is a promising tool for treating aggressive MS....
Posted 02/05/2022
... In another study, researchers found that Black people have a higher risk of dying from MS at an earlier age than white people.Population studies suggest that MS mortality rates increase with age. ...
... These nutrients may help reduce inflammation and may lower the risk of MS.For example, a study in Norway found that between 1963 and 1983, people who lived in coastal regions and ate more fish had lower rates of MS than those living inland and eating less fish. ...
... In a systematic review of studies (a look at all relevant research) of vitamin D and mental health in people with MS, researchers determined that deficiency may be a factor in higher rates of depression among people with MS. ...
6 Facts To Know Before Buying Vitamins for MS
... In a systematic review of studies (a look at all relevant research) of vitamin D and mental health in people with MS, researchers determined that deficiency may be a factor in higher rates of depression among people with MS. ...
... Review, Critical Appraisal, and Mapping of the Epidemiological Evidence — Journal of Global Health Interplay Between Epstein-Barr Virus Infection and Environmental Xenobiotic Exposure in Cancer — Infectious Agents and Cancer Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort — Frontiers in Neurology Cancer Incidence and Mortality Rates ...
Epstein-Barr Virus: A Link Between MS and Cancer
... Review, Critical Appraisal, and Mapping of the Epidemiological Evidence — Journal of Global Health Interplay Between Epstein-Barr Virus Infection and Environmental Xenobiotic Exposure in Cancer — Infectious Agents and Cancer Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort — Frontiers in Neurology Cancer Incidence and Mortality Rates ...
... In these studies, people with a lower socioeconomic status had higher rates of MS. It is not entirely clear why this is. Certain environmental risk factors may play a role. For example, people with higher socioeconomic status may be exposed to fewer germs while growing up. ...
Factors in Distribution of Multiple Sclerosis
... In these studies, people with a lower socioeconomic status had higher rates of MS. It is not entirely clear why this is. Certain environmental risk factors may play a role. For example, people with higher socioeconomic status may be exposed to fewer germs while growing up. ...
... In the United States, MS rates are also higher in the northern half of the country. ...
... Hispanic Americans with MS, in addition to having higher disability scores than their white counterparts, also have the highest rates of pain, depression, and anxiety of any racial group among those with MS.Researchers for the CHIMES study are recruiting participants ages 18 to 65 who self-identify as Black or Hispanic American. ...
Posted 12/10/2021
Study of MS Drug Ocrevus Seeks Black and Hispanic Participants
... Hispanic Americans with MS, in addition to having higher disability scores than their white counterparts, also have the highest rates of pain, depression, and anxiety of any racial group among those with MS.Researchers for the CHIMES study are recruiting participants ages 18 to 65 who self-identify as Black or Hispanic American. ...
Posted 12/10/2021
... DMTs that have been categorized as highly effective include: Alemtuzumab (Lemtrada) Natalizumab (Tysabri) and its biosimilar natalizumab-sztn (Tyruko) Ocrelizumab (Ocrevus, Ocrevus Zunovo) Ofatumumab (Kesimpta) Ublituximab (Briumvi) Cladribine (Mavenclad) These therapies have shown strong results in reducing relapse rates, preventing new brain lesions ...
Most Effective Treatments for MS: Benefits and Side Effects
... DMTs that have been categorized as highly effective include: Alemtuzumab (Lemtrada) Natalizumab (Tysabri) and its biosimilar natalizumab-sztn (Tyruko) Ocrelizumab (Ocrevus, Ocrevus Zunovo) Ofatumumab (Kesimpta) Ublituximab (Briumvi) Cladribine (Mavenclad) These therapies have shown strong results in reducing relapse rates, preventing new brain lesions ...
Join
